NYSEFinancialsFinancial Data & Stock ExchangesSnapshot 2026-07-31
Reading FDS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Recent financial performance freshly dropped to the bottom half of its industry.
View ThesisRevenue is growing steadily — about 7% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, the balance sheet.
View ManagementExpectations look high — the market is pricing in about 20% growth a year, above the roughly 6% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 53% in its worst 12-month stretch.
View RiskFactSet's growth depends on its ability to expand organic ASV by $130M to $160M in FY 2026. Recent earnings showed a 6.4% year-over-year revenue increase and a positive earnings surprise. It trades at 15× P/E, which is above the peer median of 12×. The market is pricing in more growth than expected, suggesting it looks expensive. A specific risk is that management is behind on commitments, which could hurt performance. Peer multiples imply a price about 20% below where it trades; this read is provisional.
Trailing returns as of 2026-07-31. FDS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 19 analysts currently covering FDS (as of Jul 2026).
Based on 11 Wall Street analysts offering 12-month price targets for FDS in the last 4 months.
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Financial Exchanges & Data — fair value, gap to price, and forward P/E.
Advances: Increase Organic ASV by $130M to $160M in FY 2026
Expanding insurance reach supports organic ASV growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $263.20
The last 12 months of price, then the range of analyst 12-month targets from today’s $263.20.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Expand Revenue to $2,450M to $2,470M in FY 2026
Disappointing outlook may hinder revenue growth objectives.
Advances: Increase Organic ASV by $130M to $160M in FY 2026
Strong ASV growth supports the objective for FY 2026.
Advances: Expand Revenue to $2,450M to $2,470M in FY 2026
Signals strong revenue growth and cost management.
Advances: Increase Organic ASV by $130M to $160M in FY 2026
AI adoption supports organic ASV growth target.
Threatens: Expand Revenue to $2,450M to $2,470M in FY 2026
Mixed guidance raises concerns about revenue growth.
Advances: Expand Revenue to $2,450M to $2,470M in FY 2026
Beating revenue expectations supports growth objectives.
Threatens: Expand Revenue to $2,450M to $2,470M in FY 2026
Analyst downgrade indicates potential revenue growth concerns.
